Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

Rhea-AI Summary

Evofem Biosciences reported financial results for Q2 2024, showing significant improvements:

- Net product sales increased 69% to $4.2 million
- Operating loss improved 81% to $1.4 million
- Total operating expenses decreased 43% to $5.5 million

Key developments include:
- Acquisition of global rights to SOLOSEC, a single-dose antibiotic for sexual health infections
- Licensing of Phexxi commercial rights in the Middle East
- Partnership with Hello Alpha to offer Phexxi as hormone-free contraception
- 7.4% lower rebate on Phexxi prescriptions to Medi-Cal
- Issuance of fifth U.S. patent for Phexxi

The company received $2.0 million from Aditxt, Inc. to reinstate the Merger Agreement and through preferred stock sale.

Positive

• Net product sales increased 69% year-over-year to $4.2 million
• Operating loss improved 81% to $1.4 million compared to Q2 2023
• Total operating expenses decreased 43% to $5.5 million
• Acquired global rights to SOLOSEC, expanding product portfolio
• Licensed Phexxi commercial rights in the Middle East, expanding market reach
• Negotiated 7.4% lower rebate on Phexxi prescriptions to Medi-Cal
• Strengthened intellectual property with fifth U.S. patent for Phexxi
• Received $2.0 million from Aditxt, Inc. for merger agreement and preferred stock sale

Negative

• Still operating at a loss of $1.4 million in Q2 2024
• Low cash position with only $0.7 million in restricted cash as of June 30, 2024

Financial Analyst

Evofem's Q2 2024 results show significant operational improvements, but challenges remain. Net product sales increased 69% to $4.2 million, primarily due to a one-time factor. The 81% reduction in operating loss to $1.4 million is impressive, driven by a 43% decrease in operating expenses. However, the company's liquidity position is concerning, with only $0.7 million in restricted cash. The acquisition of SOLOSEC and Middle East licensing deal for Phexxi could diversify revenue streams, but their impact remains to be seen. The pending merger with Aditxt adds uncertainty to Evofem's future. While progress is evident, sustained profitability and cash flow generation are important for long-term viability.

Medical Research Analyst

Evofem's strategic moves in women's health are noteworthy. The acquisition of SOLOSEC, a single-dose antibiotic for bacterial vaginosis and trichomoniasis, addresses significant unmet needs in sexual health. This complements Phexxi, their hormone-free contraceptive, creating a more comprehensive portfolio. The partnership with Hello Alpha to offer Phexxi via telemedicine is timely, especially for women using GLP-1 drugs who need non-hormonal options. The fifth U.S. patent for Phexxi strengthens their intellectual property position. However, more clinical data on real-world effectiveness and safety profiles of both products will be important for long-term market penetration and physician adoption.

Market Research Analyst

Evofem's market strategy shows promise but faces hurdles. The Middle East licensing deal for Phexxi opens new markets, while partnerships with Hello Alpha and Modern Remedies enhance distribution. The 7.4% lower Medi-Cal rebate could improve margins in California, a significant market. However, the 8% increase in Phexxi ex-factory unit sales suggests modest growth. The women's health market is competitive and Evofem's success will depend on effectively differentiating Phexxi and SOLOSEC. The focus on "better choices" for women aligns with current trends, but marketing execution and education efforts will be critical. The company needs to translate its strategic moves into substantial, sustained revenue growth to prove its business model.

— Improved loss from operations by 81% —

— Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections —

— Forged ex-U.S. commercial agreement for Phexxi in Middle East —

SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include:

• Acquired global rights to SOLOSEC® (secnidazole) 2g oral granules, a single-dose oral antibiotic FDA approved to treat two common sexual health infections - bacterial vaginosis and trichomoniasis.
• Licensed Phexxi® (lactic acid, citric acid and potassium bitartrate) commercial rights in the Middle East to Emirati pharmaceutical company Pharma 1 Drug Store.
• Partnered with leading telemedicine company Hello Alpha to add Phexxi to its commercial offering as a hormone-free contraception solution for women, especially those on GLP-1s and others looking for hormone-free birth control.
• Negotiated a 7.4% lower rebate on Phexxi prescriptions to Medi-Cal, the California state Medicaid program service covering more than 15.4 million lives.
• Launched a partnership with Modern Remedies, one of the top pharmacies in the Northeast, to dispense Phexxi.
• Strengthened intellectual property with the issuance and Orange Book listing of the fifth U.S. patent covering Phexxi.
• Delivered net sales of $4.2 million for the second quarter of 2024, an increase of 69% compared to the prior year quarter.
• Reduced total operating expenses to $5.5 million, a 43% decrease compared to the prior year quarter.
• Improved loss from operations 81% versus the prior year quarter to $1.4 million.
• Received $2.0 million from Aditxt, Inc. (Nasdaq: ADTX), including $1.0 million in May 2024 to reinstate the Merger Agreement and $1.0 million from the sale of preferred stock to Aditxt in July and August 2024. Under the recently amended and restated Merger Agreement, the companies are working to close the contemplated transaction in late 2024.

"Evofem continues to prove that with a disciplined and committed team we can maneuver through challenges in the market and successfully execute our strategy to expand and diversify our revenue stream. In addition to delivering strong second quarter results, we closed two transformative business development deals that will improve access to differentiated treatment options that impact women's daily lives," said Saundra Pelletier, CEO of Evofem Biosciences. "Women don't need more choices; they need better ones, and Evofem will continue to deliver on that promise."

Financial Results

For the three months ended June 30, 2024, net product sales were $4.2 million compared to $2.5 million in the prior year period. The 69% increase primarily reflects an atypically high volume of product returns in the prior year quarter, which was not repeated in the current period.  An 8% increase in Phexxi ex-factory unit sales in the current period also contributed to the year-over-year growth.

Total operating expenses were $5.5 million, a decrease of 43% compared to the prior year period.

• Selling and marketing costs were essentially unchanged at $2.2 million for the second quarter of each year.
• General and administrative costs were $2.3 million, a decrease of 54% compared to the prior year quarter.
• Research and development costs were $0.3 million, a decrease of 33% compared to the prior year quarter.
• Cost of goods sold (COGS) were $0.8 million, a 66% decrease compared to the prior year period primarily due to two items that resulted in atypically high COGS in the second quarter of 2023: i) a recorded increase in the inventory excess and obsolescence reserve, and ii) the effect of re-packaging to reflect the extended shelf life approved by the FDA in June 2022.

As a result, operating loss improved to $1.4 million for the second quarter of 2024 as compared to an operating loss of $7.3 million in the second quarter of 2023.

Net income attributable to common stockholders was $1.3 million, or $0.02 per share, for the three months ended June 30, 2024, due to a gain in other income/expense related primarily to the fair value adjustment of the financial instruments. This compares to a net loss attributable to common shareholders of $8.6 million, or $(5.43) per share, for the prior year quarter.

Liquidity
In May 2024, we received $1.0 million from Aditxt in consideration for reinstating and amending the Merger Agreement, as amended, between the companies (A&R Merger Agreement).

At June 30, 2024, Evofem had $0.7 million of restricted cash, as compared to $0.6 million of restricted cash at December 31, 2023.

In July and August 2024, we raised $1.0 million in aggregate net proceeds through the sale and issuance of 1,000 shares of Series F-1 Convertible Preferred Stock to Aditxt pursuant to the A&R Merger Agreement.

About Evofem Biosciences
Evofem Biosciences, Inc., is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi^® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.

In July 2024 Evofem broadened its commercial offering with the acquisition of SOLOSEC® (secnidazole) 2g oral granules, an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. 

In December 2023, Evofem entered into a Merger Agreement with Aditxt, Inc. (Nasdaq: ADTX) under which Aditxt intends to acquire Evofem. The parties amended and restated the Merger Agreement, as amended, in its entirety in July 2024 and are targeting to close in late 2024.

Follow us on:

LinkedIn: https://www.linkedin.com/company/evofem
Facebook: http://www.facebook.com/Evofem
X (f/k/a Twitter): https://x.com/Evofem

Phexxi^® and SOLOSEC^® are registered trademarks of Evofem Biosciences, Inc.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to the Company's anticipated financial performance, expected timing to relaunch SOLOSEC, and the likelihood of success and anticipated timing to close the contemplated Aditxt transaction. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 27, 2024, Quarterly Report on Form 10-Q for the three months ended March 31, 2024 filed with the SEC on May 12, 2024, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
ir@evofem.com

-- Financial Tables Follow –

 

EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except par value and share data)
		As of
		June 30, 2024				December 31, 2023
Assets
Current assets:
Cash and cash equivalents		$	-			$	-
Restricted cash			692				580
Trade accounts receivable, net			4,617				5,738
Total current liabilities			73,178				72,463
Total stockholders' deficit			(69,315)				(66,510)
Total liabilities, convertible and redeemable preferred stock and stockholders' deficit		$	8,551			$	10,554

 

EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share data)
		2024				2023				2024				2023
		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Product sales, net		$	4,160			$	2,458			$	7,763			$	8,267
Operating Expenses:
Cost of goods sold			769				2,293				1,453				3,669
Research and development			270				402				864				942
Selling and marketing			2,243				2,197				4,588				6,051
General and administrative			2,267				4,902				5,091				8,520
Total operating expenses			5,549				9,794				11,996				19,182
Loss from operations			(1,389)				(7,336)				(4,233)				(10,915)
Other income (expense):
Interest income			6				8				10				26
Other income (expense), net			(558)				(1,127)				(1,174)				(1,445)
Loss on issuance of financial instruments			(25)				(27)				(3,300)				(111)
Gain on debt extinguishment			-				-				1,120				-
Change in fair value of financial instruments			3,325				(73)				4,127				1,539
Total other income (expense), net			2,748				(1,219)				783				9
Income (loss) before income tax			1,359				(8,555)				(3,450)				(10,906)
Income tax expense			(8)				(3)				(8)				(6)
Net income (loss)			1,351				(8,558)				(3,458)				(10,912)
Convertible preferred stock deemed dividends			(47)				-				(94)				-
Net income (loss) attributable to common stockholders		$	1,304			$	(8,558)			$	(3,552)			$	(10,912)
Net income (loss) per share attributable to common stockholders:
Basic		$	0.02			$	(5.43)			$	(0.07)			$	(6.60)
Diluted		$	(0.00)			$	(5.43)			$	(0.07)			$	(6.60)
Weighted-average shares used to compute net income (loss) per share attributable to common shareholders:
Basic			66,773,313				1,576,158				48,983,853				1,654,026
Diluted			1,613,722,212				1,576,158				48,983,853				1,654,026

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-announces-financial-results-for-the-second-quarter-of-2024-302222084.html

SOURCE Evofem Biosciences, Inc.

FAQ

What were Evofem Biosciences' (EVFM) Q2 2024 net product sales?

Evofem Biosciences reported net product sales of $4.2 million for Q2 2024, representing a 69% increase compared to the same period in the previous year.

How much did Evofem Biosciences (EVFM) improve its operating loss in Q2 2024?

Evofem Biosciences improved its operating loss by 81% in Q2 2024, reducing it to $1.4 million compared to $7.3 million in Q2 2023.

What major acquisition did Evofem Biosciences (EVFM) make in Q2 2024?

Evofem Biosciences acquired global rights to SOLOSEC, a single-dose oral antibiotic FDA-approved to treat bacterial vaginosis and trichomoniasis.

How much funding did Evofem Biosciences (EVFM) receive from Aditxt in Q2 2024?

Evofem Biosciences received $2.0 million from Aditxt, Inc., including $1.0 million to reinstate the Merger Agreement and $1.0 million from the sale of preferred stock.